Figure 1. The expression profile of T-ALL cells in cases 1, 2, and 3. T-ALL: T-cell acute lymphoblastic leukemia/lymphoma.
| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website http://www.thejh.org |
Case Report
Volume 8, Number 3, September 2019, pages 137-140
Gamma-Delta T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Immunophenotype of Three Adult Cases
Figure
Tables
| Case No. | Sex | Age | Status | Bone marrow involvement | Mediastinal involvement | Lymphadenopathy | Hepatosplenomegaly | Skin involvement |
|---|---|---|---|---|---|---|---|---|
| 1 | Female | 66 | Untreated | + | + | - | - | - |
| 2 | Female | 31 | Refractory | + | - | - | - | - |
| 3 | Male | 29 | Refractory | + | - | + | - | - |
| Case No. | Percentage of abnormal T cells %a | Immunophenotype | TCRγδ rearrangement | |||
|---|---|---|---|---|---|---|
| High | Positiveb | Dimb | Negative | |||
| TCR: T-cell antigen receptor. aThe percentage of abnormal T cells in the bone marrow nucleated cells. bThe percentage of cells in the abnormal T cells. | ||||||
| 1 | 20.1 | CD7, CD99 | cCD3, sCD3, TCRγδ, CD45, CD5, CD34 (22.9%), CD1a (32.1%), CD117 (54.97%), CD10 (15.47%) | cTdT | cMPO, CD11b, CD13, CD15, CD33, CD11c, CD14, CD64, DR, CD19, cCD22, cCD79a, TCRαβ, CD2, CD4, CD8, CD16, CD57, CD56 | Positive |
| 2 | 19.6 | CD7, CD99 | cCD3, sCD3, TCRγδ, CD45, CD34 (46.1%), CD5, CD10 (83.8%) | CD8, cTdT (75.2%) | cMPO, CD117, CD11B, CD13, CD15, CD33, CD11c, CD14, CD64, DR, CD19, cCD22, cCD79a, TCRαβ, CD1a, CD2, CD4, CD16, CD57, CD56 | Positive |
| 3 | 27.7% | CD7, CD99 | cCD3, sCD3, TCRγδ, CD45, CD5, CD2 | cTdT (24.6%), CD10 (9.4%), CD8 (75.4%) | cMPO, CD117, CD11b, CD13, CD15, CD33, CD11c, CD14, CD64, DR, CD19, cCD22, cCD79a, TCRαβ, CD1a, CD4,CD16, CD57, CD56, CD34 | Positive |